NCT05752890View on ClinicalTrials.gov

A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma

Not yet recruitingOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 31, 2031

Study Completion Date

January 31, 2031

Conditions
Hepatocellular CarcinomaHepatitis b VirusRadiotherapyBiomarker
All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter